Shares of Cencora, Inc. (NYSE:COR – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $238.78.
Several equities analysts recently weighed in on COR shares. Robert W. Baird lifted their price target on Cencora from $280.00 to $285.00 and gave the company an “outperform” rating in a research note on Tuesday, July 9th. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. SVB Leerink reissued an “outperform” rating and issued a $275.00 price target on shares of Cencora in a research note on Thursday, June 27th. Finally, Citigroup upped their price objective on shares of Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th.
Read Our Latest Analysis on Cencora
Cencora Stock Down 0.2 %
Cencora (NYSE:COR – Get Free Report) last posted its earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, beating the consensus estimate of $3.65 by $0.15. The firm had revenue of $68.41 billion during the quarter, compared to analyst estimates of $70.60 billion. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $3.50 EPS. As a group, sell-side analysts anticipate that Cencora will post 13.46 earnings per share for the current year.
Cencora Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 10th were issued a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 0.90%. The ex-dividend date was Thursday, May 9th. Cencora’s dividend payout ratio is currently 22.32%.
Insider Buying and Selling
In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the business’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $63,323,746.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gina Clark sold 1,874 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $223.86, for a total transaction of $419,513.64. Following the sale, the executive vice president now owns 13,284 shares of the company’s stock, valued at approximately $2,973,756.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,899,112 shares of company stock worth $408,654,376. 15.80% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Cencora
Several large investors have recently modified their holdings of the business. Rise Advisors LLC acquired a new stake in shares of Cencora during the 1st quarter worth about $25,000. New Millennium Group LLC acquired a new stake in shares of Cencora during the second quarter valued at about $26,000. Legacy Bridge LLC purchased a new stake in shares of Cencora in the 1st quarter valued at approximately $27,000. TCTC Holdings LLC acquired a new position in shares of Cencora in the 1st quarter worth approximately $29,000. Finally, TFO Wealth Partners LLC acquired a new position in shares of Cencora in the 1st quarter worth approximately $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.
About Cencora
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Further Reading
- Five stocks we like better than Cencora
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Survey: Top 175 Fittest Retirement Locations in America
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What Makes a Stock a Good Dividend Stock?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.